Wound healing: from embryos to adults and back again

The Lancet

Volumn 373, Issue 9671, 2009, Pages 1226-1228

  Tredget, Edward E ^a   Ding, Jie ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AVOTERMIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ARTICLE; BURN SCAR; CLINICAL TRIAL; FIBROSIS; HUMAN; HYPERTROPHIC SCAR; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE DRUG DOSE; VISUAL ANALOG SCALE; WOUND HEALING;

EID: 64049087600     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60705-4     Document Type: Note

References (16)

1. Ferguson M.W.J., Duncan J., Bond J., et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 373 (2009) 1264-1274
2. Ladak A, Tredget EE. Pathophysiology and management of the burn scar. In: Cartotto R, ed. Clinics in plastic surgery. Philadelphia: Elsevier Saunders (in press).
3. Scott P.G., Ghahary A., Chambers M.M., and Tredget E.E. Biological basis of hypertrophic scarring. Adv Structural Biol 3 (1994) 157
4. Lakatos H.F., Thatcher T.H., Kottmann R.M., Garcia T.M., Phipps R.P., and Sime P.J. The role of PPARs in lung fibrosis. PPAR Res 2007 (2007) 71323
5. Armour A., Scott P.G., and Tredget E.E. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen 15 suppl 1 (2007) S6-S17
6. Cutroneo K.R. TGF-β-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 15 suppl 1 (2007) S54-S60
7. Roberts A.B., and Sporn M.B. The transforming growth factor-betas. In: Roberts A.B., and Sporn M.B. (Eds). Peptide growth factors and their receptors (1990), Springer, Heidelberg 421-472
8. De Crescenzo G., Hinck C.S., Shu Z., et al. Three key residues underlie the differential affinity of the TGFβ isoforms for the TGF-β type II receptor. J Mol Biol 355 (2006) 47-62
9. Hansen W., Westendorf A.M., and Buer J. Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation. Inflamm Allergy Drug Targets 7 (2008) 217-223
10. Sheid A., Wenger R.H., Schaffer L., et al. Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor β3. FASEB J 16 (2002) 411-413
11. Proetzel G., Pawlowski S.A., Wiles M.V., et al. Transforming growth factor-β3 is required for secondary palate fusion. Nat Genet 11 (1995) 409-414
12. Shah M., Foreman D.M., and Ferguson M.W.J. Neutralization of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 108 (1995) 985-1002
13. Kohama K., Nonaka K., Hosokawa R., Shum L., and Ohishi M. TGF-beta3 promotes scarless repair of cleft lip in mouse fetuses. J Dent Res 81 (2002) 688-694
14. Duncan J.A., Bond J.S., Mason T., et al. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality?. Plast Reconstr Surg 118 (2006) 909-918
15. Tredget E.E., Yang L., Delehanty M., Shankowsky H., and Scott P.G. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res 26 (2006) 179-189
16. Dunkin C.S., Pleat J.M., Gillespie P.H., Tyler M.P., Roberts A.H., and McGrouther D.A. Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers. Plast Reconstr Surg 119 (2007) 1722-1732